•  
  •  
  •  
  •  

2025-11-25 16:06:28

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cantabil Unveils Autumn-Winter 2025 Collection: Claim Your Moment
  • Crisil Ratings : Data centre operators' revenue to surge 20-22% annually till fiscal 2028
  • Servotech Renewable Granted Patent for CCS2 to GB/T EV Charging Conversion Technology
  • Navi AMC launches first-of-its-kind: Navi Nifty MidSmallcap 400 Index Fund
  • New Year, New Destinations: IndiGo Announces Black Friday Sale

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Eris Lifesciences to consolidate its stake in Swiss Parenterals
  • Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD
  • Aptus Pharma Ltd enters into Urology therapy segment
  • GMP Inspection by Ministry of Health, Armenia at Alkem's manufacturing facility located at Sikkim, India
  • Shilpa Medicare Ltd receives 8 observations from USFDA for Unit 4 at Jadcherla
  • Syncom Formulations India Ltd acquires commercial property
  • Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
  • NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai
  • Ind-Swift Laboratories Ltd receives certifications from Bureau Veritas
  • Alkem launches probiotic 'DSS', the original De Simone formulation, in India for gut health management
  • Hester Biosciences Ltd appoints Mr. Ashish Desai as CFO and KMP
  • Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
  • SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger
  • Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
  • AstraZeneca Pharma India Ltd and Sun Pharma partner to help patients living with Hyperkalaemia in India
  • Relonchem Limited receives Marketing Authorization for its two products
  • Lupin announces closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Glenmark Pharmaceuticals Announces Q2FY26 Results
  • Kilitch Drugs' PAT rises by 18% YoY to 10.30 crore in H1 FY26
  • Caplin Point Laboratories Ltd's arm acquires land in Mexico
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities Ltd
  • USFDA inspects Unit 1 of Divi's Laboratories Limited

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Cantabil Unveils Autumn-Winter 2025 Collection: Claim Your Moment
  • Crisil Ratings : Data centre operators' revenue to surge 20-22% annually till fiscal 2028
  • Servotech Renewable Granted Patent for CCS2 to GB/T EV Charging Conversion Technology
  • Navi AMC launches first-of-its-kind: Navi Nifty MidSmallcap 400 Index Fund
  • New Year, New Destinations: IndiGo Announces Black Friday Sale


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024